Back to Global NewsPublished: 18 Feb 2026Download AppJoin TelegramWhy J&J's $1B Cell Therapy Plant Could Flip the U.S. Pharma Landscape#Johnson & Johnson#Cell Therapy#Biomanufacturing#US Pharma Investment#Healthcare Stocks#InfrastructureDownload AppJoin CommunityShare Article